BioCentury | Aug 29, 2005
Finance

Ebb & Flow

Dov (DOVP) fell $2.98 (17%) to $14.99 on 5.2 million shares on Friday after suspending dosing in a Phase III trial of ocinaplon to treat generalized anxiety disorder. The suspension followed enzyme elevations in liver...
BC Week In Review | Nov 1, 2004
Company News

Myriad Genetics management update

Myriad Genetics Inc. (MYGN), Salt Lake City, Utah   Business: Pharmacogenetics   Hired: Mark Anderson as VP of chemistry at MYGN's Myriad Pharmaceuticals Inc. subsidiary, formerly director of medicinal chemistry at Elitra Pharmaceuticals Inc. ;...
BC Week In Review | Sep 27, 2004
Company News

AlgoRx management update

AlgoRx Pharmaceuticals Inc. , Secaucus, N.J.   Business: Neurology   Hired: Paul Hamelin as president and COO, formerly president and CEO of Elitra Pharmaceuticals Inc.  ...
BioCentury | May 31, 2004
Product Development

Cracking antifungals

For decades, the mainstays for treating fungal infections have come from two compound classes: azoles, which were introduced in the late 1960s, and polyenes, which were introduced in the 1950s. Today, there are two additional...
BC Week In Review | Jun 30, 2003
Company News

Elitra management update

Elitra Pharmaceuticals Inc. , San Diego, Calif.   Business: Infectious diseases   Promoted: Paul Hamelin to CEO and a director, from COO, while remaining president; he replaces Harry Hixson, who remains chairman  ...
BC Extra | Jun 26, 2003
Company News

Elitra promotes Hamelin to CEO

Antibacterial company Elitra (San Diego, Calif.) promoted Paul Hamelin to CEO and a director from COO. He retains his title of president and replaces former CEO Harry Hixson, who remains chairman....
BC Week In Review | Feb 24, 2003
Company News

Elitra, Kaken Pharmaceutical Co. Ltd. deal

The companies partnered to develop anti-fungal therapeutics. Elitra will conduct high throughput screening against targets and is responsible for certain preclinical development efforts. Kaken also will contribute to preclinical development, and both companies will coordinate...
BC Week In Review | Jan 20, 2003
Company News

Sequenom board of directors update

Sequenom Inc. (SQNM), San Diego, Calif.   Business: Diagnostics/Imaging, High throughput screening   Appointed: Harry Hixson, chairman and CEO of Elitra Pharmaceuticals Inc.  ...
BioCentury | Dec 9, 2002
Finance

Tracking Millennium's departures

Tracking Millennium's departures Name Week departed (new company) Position at MLNM Notes Charles Homcy 12/9/02 President of R&D Joined MLNM in 2002 via Cor acquisition; will continue to sit on MLNM's board John Maraganore 12/9/02...
BC Week In Review | Oct 21, 2002
Company News

Nereus management update

Nereus Pharmaceuticals Inc. , San Diego, Calif.   Business: Cancer, Infectious diseases, Autoimmune/Inflammation   Hired: Deborah Mosca as VP of research, formerly VP of drug development at Elitra Pharmaceuticals Inc.  ...
Items per page:
1 - 10 of 42
BioCentury | Aug 29, 2005
Finance

Ebb & Flow

Dov (DOVP) fell $2.98 (17%) to $14.99 on 5.2 million shares on Friday after suspending dosing in a Phase III trial of ocinaplon to treat generalized anxiety disorder. The suspension followed enzyme elevations in liver...
BC Week In Review | Nov 1, 2004
Company News

Myriad Genetics management update

Myriad Genetics Inc. (MYGN), Salt Lake City, Utah   Business: Pharmacogenetics   Hired: Mark Anderson as VP of chemistry at MYGN's Myriad Pharmaceuticals Inc. subsidiary, formerly director of medicinal chemistry at Elitra Pharmaceuticals Inc. ;...
BC Week In Review | Sep 27, 2004
Company News

AlgoRx management update

AlgoRx Pharmaceuticals Inc. , Secaucus, N.J.   Business: Neurology   Hired: Paul Hamelin as president and COO, formerly president and CEO of Elitra Pharmaceuticals Inc.  ...
BioCentury | May 31, 2004
Product Development

Cracking antifungals

For decades, the mainstays for treating fungal infections have come from two compound classes: azoles, which were introduced in the late 1960s, and polyenes, which were introduced in the 1950s. Today, there are two additional...
BC Week In Review | Jun 30, 2003
Company News

Elitra management update

Elitra Pharmaceuticals Inc. , San Diego, Calif.   Business: Infectious diseases   Promoted: Paul Hamelin to CEO and a director, from COO, while remaining president; he replaces Harry Hixson, who remains chairman  ...
BC Extra | Jun 26, 2003
Company News

Elitra promotes Hamelin to CEO

Antibacterial company Elitra (San Diego, Calif.) promoted Paul Hamelin to CEO and a director from COO. He retains his title of president and replaces former CEO Harry Hixson, who remains chairman....
BC Week In Review | Feb 24, 2003
Company News

Elitra, Kaken Pharmaceutical Co. Ltd. deal

The companies partnered to develop anti-fungal therapeutics. Elitra will conduct high throughput screening against targets and is responsible for certain preclinical development efforts. Kaken also will contribute to preclinical development, and both companies will coordinate...
BC Week In Review | Jan 20, 2003
Company News

Sequenom board of directors update

Sequenom Inc. (SQNM), San Diego, Calif.   Business: Diagnostics/Imaging, High throughput screening   Appointed: Harry Hixson, chairman and CEO of Elitra Pharmaceuticals Inc.  ...
BioCentury | Dec 9, 2002
Finance

Tracking Millennium's departures

Tracking Millennium's departures Name Week departed (new company) Position at MLNM Notes Charles Homcy 12/9/02 President of R&D Joined MLNM in 2002 via Cor acquisition; will continue to sit on MLNM's board John Maraganore 12/9/02...
BC Week In Review | Oct 21, 2002
Company News

Nereus management update

Nereus Pharmaceuticals Inc. , San Diego, Calif.   Business: Cancer, Infectious diseases, Autoimmune/Inflammation   Hired: Deborah Mosca as VP of research, formerly VP of drug development at Elitra Pharmaceuticals Inc.  ...
Items per page:
1 - 10 of 42